Nuwellis to Report Third Quarter 2026 Financial Results on November 12
Nuwellis (NUWE) will report third-quarter 2026 financial results before U.S. financial markets open on November 12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuwellis (NUWE) will report third-quarter 2026 financial results before U.S. financial markets open on November 12, 2026.
The results will cover the three and nine months ended September 30, 2026. The company will host a conference call at 9:00 a.m. Eastern time that day, with a live and replay webcast available through its investor relations website.
Key Figures
- Results announcement date
- November 12, 2026
- Third-quarter and nine-month financial results, before market open
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 12, 2026, and will host a conference call beginning at 9:00 a.m. Eastern time.
Conference Call & Webcast Information
Date: Thursday, November 12th
Time: 9:00 a.m. Eastern time
Domestic Dial-in: (833) 309-3473
International Dial-in: (785) 838-9251
Conference ID: NUWEQ3
Live and Replay Webcast: https://ir.nuwellis.com or available here
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.
For further information, please contact:
Investor Relations:
CORE IR
ir@nuwellis.com
Media Contact:
CORE PR
media@nuwellis.com
